SAFC will extend its focus on high potency production through a number of new investments.
The company – who recently expanded its potent API capabilities at its plant in Jerusalem, Israel – announced its plans for further expansion in the sector during its conference at its liquid media facility in Glasgow.
Members of the biopharma and chemicals company also delivered talks on the changing nature of biosimilars and biobetters in the industry and how companies can benefit from it.
In-pharmatechnologist caught up with SAFC’s VP, global sales, Archie Cullen, as well as Grant Boldt, director of European business development, for the latest news.
QC manager for the firm’s Irvine facility, Susan Longhorn, also spoke about the companies four key areas for quality management, as well as working with regulatory agencies in today’s market.